Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors	Solid Tumor Cancer; Solid Tumor Cancer Treatment With Immunotherapy	Recruiting	Phase 1	2026-05-13		NCT07584954

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Anyang Tumor Hospital	12
Fudan University	653
Fujian Cancer Hospital	114
Hunan Cancer Hospital	66
Jun Zhou	1
Shandong Cancer Hospital and Institute	71
Shanghai Pulmonary Hospital, Shanghai, China	98
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	91

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anyang tumor hospital	Anyang	China	8
Cancer Hospital of Shandong First Medical University	Jinan	China	8
Fudan University Shanghai Cancer Center	Shanghai	China	128
Fujian Cancer Hospital	Fuzhou	China	55
Shanghai Pulmonary Hospital	Shanghai	China	33
Shanghai Xinhua hospital	Shanghai	China	3